OptiBiotix Health PLC Presentations at ProBiota - 2019
February 20 2019 - 1:01AM
RNS Non-Regulatory
TIDMOPTI
OptiBiotix Health PLC
20 February 2019
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Presentations at ProBiota - 2019
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, announces its three abstracts at the ProBiota 2019
event between 13-15 February 2019, at Scandic Copenhagen,
Denmark.
ProBiota is the leading annual event for the global prebiotic,
probiotic and the microbiome focused food and pharma industries.
The conference is world renowned meeting place for a community of
scientists and industry leaders who want to translate the latest
science into new products in the growing supplements and
ingredients market. The three abstracts presented were as follows:
-
SweetBiotix(R): Sweet fibres with a microbiome modulating
effect
Optibiotix has a number of development programmes creating
natural sweet fibres (SweetBiotix(R)) with the potential to meet
the needs of both the natural high intensity sweetener and bulk
sugar markets. These markets are collectively forecast to reach
$112bn by 2022 (Mordor Intelligence, 2017). The abstract presented
at ProBiota reported on human studies from an expert panel of 12
flavourists of its natural high intensity sweeteners. These showed
high sweetness, reduced bitterness and reduced off-flavours when
compared to natural sweeteners like Stevia. The products were then
tested for their ability to modify microbiome composition and
activity in healthy adults. The results showed significant
increases in short-chain fatty acids ("SCFA"), the molecular
messengers produced by bacteria when they ferment fibre and
non-digestible carbohydrates. SCFA are widely known for their
importance in gut health, immunity and affect how energy is
metabolised in the body, and are one of the main ways in which the
gut microbiome contributes to better health. Whilst previous
studies (RNS: 23 January 2018) have demonstrated that these fibres
have high sweetness and no aftertaste, this is the first study to
demonstrate a positive effect on the microbiome. This creates a
clear differentiator to other sweeteners on the market and an
opportunity to replace unhealthy sugars with healthy fibres in a
range of food and beverage products and as an ingredient in its own
right. The results were well received and will be used by
OptiBiotix as leverage in existing and future commercial
discussions to optimise shareholder value.
Slimbiome(R): Clinic Impact of SlimBiome(â) on satiety,
satiation, weight loss and gut microbiome composition in overweight
and obese women
This abstract presented the results of an independent clinical
study carried out by the University of Roehampton which
demonstrated that human volunteers taking SlimBiome(R) had
statistically significant reductions in weight, BMI, hip
circumference, percentage body fat, fat mass and systolic blood
pressure (P<0.01) after four weeks of SlimBiome(â) intake.
Significant reduction in cravings for savoury foods (P<0.001)
and a trend for reduced sweet cravings were recorded from the end
of week one of the treatment onwards, accompanied by a significant
improvement in mood (P<0.01). Notable increases were observed in
the relative abundance of Christensenellaceae, Bacteroidetes and
Actinobacteria. These are bacteria within the gut microbiome which
other studies have associated with weight loss and leaner body
types. This study adds further evidence to other clinical studies
and consumer feedback which shows SlimBiome(â) has a significant
impact on food cravings and hunger, leading to easier and more
successful weight loss, typically 2-3lbs per week. The increase in
bacteria within the gut associated with weight loss in people
taking SlimBiome(R) is an exciting development and will be the
subject of further studies.
Antimicrobial activity of Lactobacillius Plantarum LP(LDL)
(R)OptiBiotix presented research on the antimicrobial activity of
L. plantarum LP(LDL) (R) pregrown on different carbohydrates,
against a selection of pathogens of clinical relevance. LP(LDL) (R)
has an established cholesterol reducing activity in normal to
mildly hypercholesterolaemic (high cholesterol levels) adults. The
studies, carried out by the University of Reading, showed LP(LDL)
(R) demonstrated antimicrobial activity against a wide range of
clinically important clinical pathogens including those known to
cause serious gastrointestinal infections around the world. These
include Campylobacter, Shigella, Salmonella, E.coli O157, and
significantly Clostridium difficile, the cause of serious hospital
acquired infections. The results of this study suggest LP(LDL) (R)
may have additional biological activities which if proven in human
studies, have the potential to widen LP(LDL) (R)'s commercial
opportunities to include gut health and the prevention of
traveller's diarrhoea. This will help support the use of LP(LDL)
(R) in a wide range of food, dairy, supplement and
biopharmaceutical products. This research gives an early indication
as to LP(LDL) (R)'s potential to extend its existing use as a
supplement into a wide range of consumer food and healthcare
products.
Commenting, Stephen O'Hara, CEO of OptiBiotix said: "We were
pleased with the high amount of scientific and commercial interest
in our presentations at ProBiota which demonstrated the breadth of
our scientific development. These studies, and the publications and
presentations from them presented at internationally renowned
events, are part of a strategy of developing microbiome products
with a strong scientific and clinical evidence base with key
opinion leader support. This provides clear product differentiation
which can be translated into evidenced based product consumer
claims. This attracts commercial interest in our technology and
products leading to a healthy deal pipeline. As we continue to
build the science around existing products and platforms and
identify new application opportunities; the scale of the
opportunity, and the potential value of OptiBiotix, increases."
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
FinnCap (Broker) Tel: 020 7220 0500
Adrian Hargrave / Scott Mathieson / Kate Bannatyne
(Corporate Finance)
Tony Quirke (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEASANFFFNEFF
(END) Dow Jones Newswires
February 20, 2019 02:01 ET (07:01 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024